Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Diabetes Obes Metab
; 18(11): 1089-1092, 2016 11.
Article
en En
| MEDLINE
| ID: mdl-27486125
ABSTRACT
Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH) from phase III studies in type 1 diabetes (T1D), insulin-naïve patients with type 2 diabetes (T2D), patients with T2D on basal insulin only and patients with T2D on basal-bolus therapy. BIL treatment had little effect on HDL cholesterol and LDL cholesterol in all patients. The effect of both BIL and glargine treatment on triglycerides (TG) depended on whether patients had been previously treated with insulin. When BIL replaced conventional insulin glargine or NPH treatments, increases in TG levels were observed. When BIL or comparator insulins were given for 26 weeks to insulin-naïve patients with T2D, TG levels were unchanged from baseline with BIL but decreased with either glargine or NPH. The decreased peripheral action of BIL may reduce suppression of lipolysis in peripheral adipose tissue resulting in increased free fatty acid delivery to the liver and, hence, increased hepatic TG synthesis and secretion.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Polietilenglicoles
/
Triglicéridos
/
Diabetes Mellitus Tipo 1
/
Diabetes Mellitus Tipo 2
/
Metabolismo de los Lípidos
/
Insulina Lispro
/
Insulina Glargina
/
Hipoglucemiantes
/
Insulina Isófana
/
Lípidos
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Diabetes Obes Metab
Asunto de la revista:
ENDOCRINOLOGIA
/
METABOLISMO
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos